PharmAla Partners with University for Innovative MDMA Research
PharmAla Collaborates with University to Advance MDMA Research
TORONTO, Oct. 08, 2024 – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF) has officially announced its role as a supplier of MDMA for an upcoming clinical trial at the University of Texas, San Antonio. With this partnership, PharmAla aims to deliver a novel dosage form of LaNeo™ MDMA, which will be pivotal in investigator-initiated human trials.
Innovative Dosage Forms Supporting Clinical Trials
“PharmAla is prepared to assist researchers with not only our existing active pharmaceutical ingredients (API) and 40mg capsules but also in creating new dosage forms of LaNeo™ MDMA,” expressed Nicholas Kadysh, CEO at PharmAla Biotech. This initiative reflects the company’s commitment to exploring varied approaches to drug delivery, recognizing the need for diverse dosing strategies for various therapeutic models.
Enhancing Patient Care Through Research
The decision to explore innovative dosage forms underscores PharmAla’s dedication to improving therapeutic outcomes using MDMA in assisted therapies. The existing 40mg dosage structure has been effective in both Canada and Australia; however, the company believes that broadening dosage options will pave the way for greater adaptability in treatment plans for patients.
Recognizing Intellectual Property Advancements
In tandem with research initiatives, PharmAla is proud to announce the recent publication of a key patent application linked to its Intellectual Property (IP) strategy by the US Patent and Trademark Office (USPTO). This application pertains to PharmAla’s APA-01 novel molecular entity, which holds promise for various medicinal applications. The significant technological advancements stem from the original APA-01 patent that was granted earlier this year.
Gratitude for Ongoing Support
Dr. Harpreet Kaur, VP of Research at PharmAla Biotech, expressed appreciation for the support received from partners like IPON. Their assistance, particularly through non-dilutive grants, has been crucial in sustaining PharmAla’s endeavors to file global patents. This collaborative spirit drives the company’s mission of realizing valuable IP opportunities within Canada.
Who is PharmAla Biotech?
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) stands at the forefront of biotechnology, with a core focus on the development and manufacture of MDXX class molecules, including MDMA. Established with the vision of addressing the pressing need for clinical-grade MDMA, PharmAla works to facilitate clinical trials while also exploring commercial viability in chosen markets. The company has made strides in its research and development endeavors, leading proof-of-concept studies into several families of intellectual property, including its promising candidate, ALA-002.
Commitment to Regulatory Excellence
Recognizing the significance of robust relationships with regulatory bodies, PharmAla is dedicated to redefining success in the psychedelics sector. The company embraces a regulatory-first approach, believing that collaboration with legislators is essential to achieve sustainable progress within this emerging industry.
For additional inquiries, please contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla Biotech Holdings Inc.?
PharmAla is a biotechnology company specializing in the research, development, and manufacturing of MDMA and other novel derivatives.
What is LaNeo™ MDMA?
LaNeo™ MDMA is a proprietary formulation of MDMA developed by PharmAla, designed for clinical and therapeutic use.
What is the significance of the University of Texas collaboration?
This collaboration aims to support innovative clinical trials that explore new dosage forms of MDMA for therapeutic applications.
How does PharmAla ensure regulatory compliance?
PharmAla maintains a regulatory-first approach, emphasizing strong relationships with regulators to ensure compliance and success in the psychedelics sector.
What are PharmAla's future goals?
PharmAla aims to expand its research initiatives and enhance its intellectual property portfolio while continuing to supply clinical-grade MDMA and novel drugs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Opportunity for Bumble Inc. Investors to Join Class Action Suit
- Opportunity for Super Micro Computer Investors Amid Legal Action
- HBT Financial Sets Date for Q3 2024 Financial Results Release
- Transform Your $1,000 Investment into Over $2,100 Today!
- Myriad Genetics Enhances Breast Cancer Research with Collaborations
- Investigation Launched for Fortrea Holdings Inc. - What You Need to Know
- Vicor Corporation Announces Earnings Call for Investors
- LTC Global Expands Its Portfolio with LTCR Acquisition
- Saratoga Investment's Impressive Q2 2025 Financial Performance
- Square Unveils Innovative Orders Platform for Sellers
Recent Articles
- Velsera and Longwood Forge Strategic Alliance for Genomics
- Bitcoin's Price Fluctuations: Analyzing Market Trends and Insights
- Critical Analyst Downgrades Affect Major Companies Today
- Transforming Wellness: The Revitalization of EEZ Co. Brand
- Market Insights: Final Trades from Owens Corning to Diamondback Energy
- JUUNOO and FRAMEWORK Team Up for Eco-Friendly Workspaces
- Upcoming Virtual Events by Parks Associates Focus on Innovation
- Jim Cramer's Insights on VICI Properties and Energy Stocks
- US Trade Deficit Improvement Highlights Economic Trends
- Bon Secours Mercy Health Collaborates on New Cardiac Facility
- Law Schools Struggle with AI Policy Implementation in Admissions
- Otis Worldwide Corporation Faces Downgrade Amid Market Concerns
- ACR Poker's OSS XL Sets New Records with $46 Million in Payouts
- MetLife's Survey Reveals a Surge in Pension Liabilities De-Risking
- CT REIT Anticipates Impressive Q3 2024 Earnings Call
- Student News Live Sets Stage for Groundbreaking Election Reporting
- UFC Star Michael Chandler Partners with Aires Tech for EMF Safety
- Tesla's Transformative Robotaxi Launch: What Investors Should Know
- Titanium Powder Market to Reach $1.4 Billion by 2032
- LakeShore Biopharma's Promising Financial Outlook for 2025
- Hedge Funds Shift Strategies Amidst Economic Uncertainty
- Celluma Light Therapy Earns Award for Innovation in Tech
- Accolade Inc's Thriving Q2: Revenue Grows and Losses Decline
- Ecopetrol S.A. Launches Tender Offer for Outstanding Notes
- Mixed Reactions to iPhone 16 Launch: Insights from KeyBanc
- STS101 Study Reveals Positive Efficacy for Migraine Treatment
- Saudi Market Trends: Notable Gains and Sector Insights
- Oncocyte's Revolutionary Advances in Breast Cancer Diagnostics
- Empowering Women in Business: The WORKBENCH Office Project
- Wheels Up Welcomes New EVP, Charting Future Strategies Ahead
- Small Business Concerns Ahead of Election Day: Insights from GoDaddy
- Tonix Pharmaceuticals Collaborates on Antiviral Drug Program
- Combat Workplace Rudeness: Insights from John O'Brien
- H+M Industrial EPC Expands Services with New Gulf Coast Office
- Kopin Corporation's SXGA-R15 Microdisplay System Revolutionizes Tech
- Innovative Telehealth Approach to Support Postpartum Women
- Baird Maintains Optimistic Stance on ESAB Corporation Growth
- Dundee Precious Metals Continues Strong Performance Amidst Challenges
- Discovering a Hidden Gem in Water Conservation Solutions
- Fair Isaac Corporation: What Analysts Are Saying Now
- Virios Therapeutics' Merger with Wex Pharmaceuticals Promises Growth
- Procept BioRobotics' Growth Momentum and Regulatory Achievements
- Rivian Faces Challenges Amid Lowered Production Forecasts
- Hungary Delays G7 Ukraine Loan Agreement Until US Elections
- Continued Growth in Gold ETFs Signals Investor Confidence
- European Stock Market Faces Q3 Earnings Challenges
- Money Supply Growth Recovery Signals Economic Resilience
- Cleveland-Cliffs Inc. Proposes $800 Million Note Offering
- Wells Fargo's Asset Cap: Exploring Future Market Movements
- PROS Holdings Set to Reveal Third Quarter 2024 Results Soon